AXONIS Therapeutics, an emerging biotechnology company, has secured an additional $5 million in funding. This financing round was led by Alexandria Venture Investments with participation by R3 Bio, BoxOne Ventures and Civilization Ventures and two leading spinal cord injury non-profit foundations, the Christopher & Dana Reeve Foundation and Spinal Research; and joined by current investors.

AXONIS Therapeutics is a biotechnology developing therapies for currently incurable neurological disorders. AXONIS Therapeutics is progressing a pipeline of neuron-reviving therapeutics which enable an intrinsic ability of central nervous system (CNS) neurons to resist degeneration; restore excitation/inhibition balance; and regenerate.